🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to Clare Weeden from WEHI (Walter and Eliza Hall Institute) who was tonight awarded a 2025 CSL Centenary Fellowship for her research on the cellular changes that can lead to lung cancer, and on ways to detect, stop and even reverse those changes. bit.ly/3UiBITS

Congratulations to @qizhang85 from South Australian immunoGENomics Cancer Institute, Uni of Adelaide who was tonight awarded a 2025 CSL Centenary Fellowship. She is investigating the fundamental processes by which our cells turn genes on and off as they change identities. bit.ly/4eWX7u2

Applications for the #CSLBehring #ProfHeimburgerAward2025 are now extended to November 18, 2024; 11:59pm CET! Visit bit.ly/40E2biU to apply. Applications are subject to eligibility #earlycareerresearchers #hematology #inheritedbleedingdisorders #acquiredbleedingdisorders

We are proud to announce we have received a positive CHMP opinion for our once-monthly treatment targeting factor Xlla for #HAE. Read more: bit.ly/3ZSGmeG.

We recently received a positive CHMP opinion for our monoclonal antibody targeting factor Xlla to prevent #HAE attacks. We’re proud to continue serving the HAE community and driving innovation forward.

🎄✨ This holiday season, we’re filled with gratitude for the moments, memories, and people that make life so special. May your days be merry, your hearts full, and your home warm with love. Wishing you a joyful Christmas! ❤️🎁 #MerryChristmas #CSL

🎉✨ Cheers to a fresh start and endless possibilities! As we welcome 2025, let’s embrace new adventures, chase big dreams, and celebrate every moment along the way. Here’s to health, happiness, and success for all in the year ahead. 🥂🎆 #HappyNewYear #CSL

We are proud to announce that Australia’s TGA has approved the first and only once-monthly treatment targeting factor XIIa to prevent attacks of #HAE. Read more: bit.ly/4htSbh6

Our first approved homegrown recombinant mAb highlights our unwavering dedication to advancing care for those with HAE – a community we have supported for over 40 years. We are committed to improving the lives of patients around the world. Read more: bit.ly/4awYH4o.

Today we shared our results for the first half of the 2025 financial year. Below is a snapshot of the financial and operational highlights. You can find more details at our investor centre: bit.ly/4hsQPUv #CSL

Our CEO and Managing Director Paul McKenzie discusses some of the highlights from our half-year results for financial year 2025. For the full presentation, including disclaimers & notes supporting financial information, visit our investor centre: bit.ly/3Q9WouX #CSL

Our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE is approved by the EC. We are committed to advancing care for people living with HAE, a community we have supported for over 40 years. Read more: bit.ly/47HgF1z.

Along with our partner ArcturusRx, we are proud to announce that the EC has approved the first self-amplifying mRNA COVID-19 vaccine in the European Union. Read more: bit.ly/47HgF1z.

The European Commission’s approval of our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE reflects our ongoing commitment to improving the lives of people living with this condition.

Japan’s MHLW approved our first-in-class monoclonal antibody for HAE, reinforcing our commitment to a community we have supported for more than 40 years. Japan joins Australia, the UK, and the EU in offering an innovative treatment to patients. Learn more: bit.ly/4bqvtVD

CSL is proud to sponsor the symposium "WHO guidance on PBM implementation: Strategies for effective dissemination and communication" at NATA. We look forward to welcoming you on Thursday 24 April at 12:15 CET!

Congratulations to the eight medical researchers who have been awarded a CSL Research Acceleration Initiative (RAI) partnership to fast-track the discovery of innovative biotherapies to address unmet medical needs. bit.ly/4cLXPKw

Applications are open for the 2026 CSL Centenary Fellowships. Australian early-mid career biomedical #researchers are invited to apply for 1 of 2 A$1.25m #grants over 5 years. bit.ly/4mcIkzk

.Clare Weeden from WEHI (Walter and Eliza Hall Institute) is doing important #research with the support of a #CSLCentenaryFellowship. Applications for 2026 are now open: bit.ly/3SmhVS7 #CSL

Dr @qizhang85 from South Australian immunoGENomics Cancer Institute, Uni of Adelaide is doing important #research with the support of a #CSLCentenaryFellowship. Applications for 2026 are now open: bit.ly/3FxGI2Z